Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zynteglo
Pharma
Bluebird discusses Lyfgenia launch details and accounting errors
Bluebird bio reported progress of its launch of three gene therapies and said it will have to refile financial statements due to accounting errors.
Kevin Dunleavy
Mar 26, 2024 10:49am
Bluebird secures $175M loan from Hercules Capital
Mar 18, 2024 11:49am
Bluebird quickly raises funds to support gene therapy launches
Dec 19, 2023 10:13am
Vertex's pricing won't affect bluebird's strategy on lovo-cel
Nov 7, 2023 3:20pm
Bluebird amends deal with Lonza to boost gene therapy capacity
Sep 28, 2023 9:29am
Bluebird touts gene therapy launches as cash remains tight
Aug 8, 2023 10:21am